Overexpression of MAL2 Correlates with Immune Infiltration and Poor Prognosis in Breast Cancer

Table 3

Correlation between MAL2 mRNA expression and clinicopathologic parameters of breast cancer.

Parameters	Variables	N	MAL2 mRNA expression				χ^2	value
			High	(%)	Low	(%)
Age	<40	75	37	6.79	38	6.97	0	1
	≥40	1015	508	93.21	507	93.03
Stage	I + II	802	392	73.82	410	75.79	—	0.044
	III + IV	270	139	26.18	131	24.21
	X	18	14	2.57	4	0.73
T classification	T1 + T2	910	466	85.82	444	81.62	—	0.115
	T3 + T4	177	77	14.18	100	18.38
	TX	3	2	0.37	1	0.18
M classification	M0	900	472	86.61	428	78.53	12.83	0.002
	M1	22	10	1.83	12	2.20
	MX	168	63	11.56	105	19.27
N classification	N0	484	233	43.15	251	46.4	—	0.399
	N1 + N2 + N3	597	307	56.85	290	53.6
	NX	9	5	0.92	4	0.73
ER status	Negative	236	103	19.92	133	25.38	5.47	0.065
	Positive	805	414	80.08	391	74.62
	Unknown	49	28	5.14	21	3.85
PR status	Negative	343	166	32.11	177	33.97	0.73	0.694
	Positive	695	351	67.89	344	66.03
	Unknown	52	28	5.14	24	4.4
HER2 status	Negative	559	282	76.01	277	78.92	2.51	0.285
	Positive	163	89	23.99	74	21.08
	Unknown	368	174	31.93	194	35.6
Vital status	Living	941	453	83.12	488	89.54	8.99	0.003
	Deceased	149	92	16.88	57	10.46

ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; PR, progesterone receptor. Note. Bold values indicate statistically significant . means Fisher’s test.